Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial

Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…

AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

One hepatitis B drug shows early functional cures in trial / 2 days

Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 5 wks

Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 15 days

First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 1 month

Pfizer's Lyme vaccine heads to FDA after mixed trial results / 2 months

WHO approves first malaria treatment for infants; Novartis drug prequalified / 5 wks

FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 5 wks